Observational studyDiabetic medicine : a journal of the British Diabetic Association2019
A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
Observational study in Diabetic medicine : a journal of the British Diabetic Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.Diabetes, obesity & metabolism · 2020Pooled it
- Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes.Diabetology & metabolic syndrome · 2024Article
- Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades.Current diabetes reviews · 2024Review
- Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review.Current diabetes reviews · 2023Review
- Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes.Paediatric drugs · 2022Review
- Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM.Diabetes/metabolism research and reviews · 2021Article
- Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience.Archives of medical sciences. Atherosclerotic diseases · 2021Article
- Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020 · on this mapReview
- A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).Diabetic medicine : a journal of the British Diabetic Association · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo conduct an open-label study to provide UK real-world evidence regarding the use of insulin glargine 300 units/ml (U300) in people with Type 1 diabetes mellitus.
methodsPeople with Type 1 diabetes who had been prescribed U300 ≥6 months before data collection and had HbA
resultsA total of 298 people with Type 1 diabetes were included [mean age 42.1 years, mean HbA
conclusionsIn people with Type 1 diabetes, a change in basal insulin to U300 was associated with clinically and statistically significant HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.